TY - JOUR
T1 - The QT interval prolongation potential of anticancer and supportive drugs
T2 - a comprehensive overview
AU - Giraud, Eline L.
AU - Ferrier, Kaylee R.M.
AU - Lankheet, Nienke A.G.
AU - Desar, Ingrid M.E.
AU - Steeghs, Neeltje
AU - Beukema, Rypko J.
AU - van Erp, Nielka P.
AU - Smolders, Elise J.
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/9
Y1 - 2022/9
N2 - Patients with cancer are prone to prolongation of the corrected QT interval (QTc) due to the use of anticancer drugs with QTc-prolonging potential in combination with electrolyte imbalances caused by, for example, gastrointestinal side-effects. However, most anticancer drugs were approved with little information on their QTc-prolonging potential and the added risk of torsade de pointes. The absence of this information on the drug label poses a considerable challenge to clinicians regarding the measures that need to be taken to safely start anticancer treatment. In this Review, we provide a comprehensive overview of the evidence for the QTc-prolonging properties of 205 anticancer drugs and 14 antiemetic drugs available from drug labels, assessment reports, and published studies. We classify the drugs as low-risk, moderate-risk, or high-risk for QTc prolongation. We also discuss the clinical relevance of these findings and include practical recommendations to guide clinicians to select the drugs with the least QTc-prolonging properties and to adequately monitor susceptible patients.
AB - Patients with cancer are prone to prolongation of the corrected QT interval (QTc) due to the use of anticancer drugs with QTc-prolonging potential in combination with electrolyte imbalances caused by, for example, gastrointestinal side-effects. However, most anticancer drugs were approved with little information on their QTc-prolonging potential and the added risk of torsade de pointes. The absence of this information on the drug label poses a considerable challenge to clinicians regarding the measures that need to be taken to safely start anticancer treatment. In this Review, we provide a comprehensive overview of the evidence for the QTc-prolonging properties of 205 anticancer drugs and 14 antiemetic drugs available from drug labels, assessment reports, and published studies. We classify the drugs as low-risk, moderate-risk, or high-risk for QTc prolongation. We also discuss the clinical relevance of these findings and include practical recommendations to guide clinicians to select the drugs with the least QTc-prolonging properties and to adequately monitor susceptible patients.
UR - http://www.scopus.com/inward/record.url?scp=85137163021&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(22)00221-2
DO - 10.1016/S1470-2045(22)00221-2
M3 - Review article
C2 - 36055309
AN - SCOPUS:85137163021
SN - 1470-2045
VL - 23
SP - e406-e415
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 9
ER -